The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Open accessAbstract
Breast cancer is the most common malignancy in women worldwide. Metastasis is the leading cause of high mortality in most cancers. Although predicting the early stage of breast cancer before metastasis can increase the survival rate, breast cancer is often discovered or diagnosed after metastasis has occurred. In general, breast cancer has a poor prognosis because it starts as a local disease and can spread to lymph nodes or distant organs, contributing to a significant impediment in breast cancer treatment. Metastatic breast cancer cells acquire aggressive characteristics from the tumor microenvironment (TME) through several mechanisms including epithelial–mesenchymal transition (EMT) and epigenetic regulation. Therefore, understanding the nature and mechanism of breast cancer metastasis can facilitate the development of targeted therapeutics focused on metastasis. This review discusses the mechanisms leading to metastasis and the current therapies to improve the early diagnosis and prognosis in patients with metastatic breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Prospective identification of tumorigenic breast cancer cells
Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., & Clarke, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0530291100 · Cited by 10,370
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“However, it is usually identified at an advanced stage at the time of diagnosis, resulting in a high recurrence rate and low survival rate [8,9].”
BackgroundNieto, M. A., Huang, R. Y.-J., Jackson, R. A., & Thiery, J. P. (2016) · Cell · doi:10.1016/j.cell.2016.06.028 · Cited by 4,492
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Ginestier, C., Hur, M. H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., Viens, P., Kleer, C. G., Liu, S., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.08.014 · Cited by 4,012
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“Some tumor-promoting immune cells such as M2 macrophage and myeloid-derived suppressor cells (MDSCs) were recruited by inflammatory cytokines including CCL2 in the TME, which enhances cell proliferation, vascularization, migration, and migration metastasis [74,75].”
BackgroundPertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Brabletz, T., Kalluri, R., Nieto, M. A., & Weinberg, R. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.118 · Cited by 1,961
The role of myeloid cells in the promotion of tumour angiogenesis
Murdoch, C., Muthana, M., Coffelt, S. B., & Lewis, C. E. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2444 · Cited by 1,642
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Pathiraja, K., Aktan, G., Cheng, J. D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8931 · Cited by 1,477
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
von Minckwitz, G., Procter, M., de Azambuja, E., Zardavas, D., Benyunes, M., Viale, G., Suter, T., Arahmani, A., Rouchet, N., Clark, E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1703643 · Cited by 1,411
Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914609 · Cited by 1,326
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115022 · Cited by 1,175
NK cells and cancer: you can teach innate cells new tricks
Morvan, M. G., & Lanier, L. L. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.5 · Cited by 1,162
Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion
Dirat, B., Bochet, L., Dabek, M., Daviaud, D., Dauvillier, S., Majed, B., Wang, Y. Y., Meulle, A., Salles, B., Le Gonidec, S., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3323 · Cited by 1,134
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
Emens, L. A., Cruz, C., Eder, J. P., Braiteh, F., Chung, C., Tolaney, S. M., Kuter, I., Nanda, R., Cassier, P. A., Delord, J.-P., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4224 · Cited by 766
Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A., & Sarkar, S. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0048-3 · Cited by 739
Iliopoulos, D., Hirsch, H. A., Wang, G., & Struhl, K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018898108 · Cited by 643
CCL18 from Tumor-Associated Macrophages Promotes Breast Cancer Metastasis via PITPNM3
Chen, J., Yao, Y., Gong, C., Yu, F., Su, S., Chen, J., Liu, B., Deng, H., Wang, F., Lin, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.006 · Cited by 641
Context-dependent EMT programs in cancer metastasis
Aiello, N. M., & Kang, Y. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181827 · Cited by 584
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
E-cadherin in contact inhibition and cancer
Mendonsa, A. M., Na, T.-Y., & Gumbiner, B. M. (2018) · Oncogene · doi:10.1038/s41388-018-0304-2 · Cited by 526
DNA Methyltransferase Inhibitors and the Development of Epigenetic Cancer Therapies
Lyko, F., & Brown, R. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji311 · Cited by 510
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Antifibrotic activities of pirfenidone in animal models
Schaefer, C. J., Ruhrmund, D. W., Pan, L., Seiwert, S. D., & Kossen, K. (2011) · European Respiratory Review · doi:10.1183/09059180.00001111 · Cited by 454 · cited 1×
“Pirfenidone, an anti-fibrotic and anti-inflammatory agent, reduces fibroblast proliferation by inhibiting the transforming growth factor-β (TGF-β) signaling pathway, a key EMT regulatory signal [58,59].”
BackgroundControversies around epithelial–mesenchymal plasticity in cancer metastasis
Williams, E. D., Gao, D., Redfern, A., & Thompson, E. W. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0213-x · Cited by 451
Breast Cancer Metastasis to the Central Nervous System
Weil, R. J., Palmieri, D. C., Bronder, J. L., Stark, A. M., & Steeg, P. S. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61180-7 · Cited by 434
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C. (2016) · Immunological Reviews · doi:10.1111/imr.12405 · Cited by 417
The microenvironment in breast cancer progression: biology and implications for treatment
Place, A. E., Jin Huh, S., & Polyak, K. (2011) · Breast Cancer Research · doi:10.1186/bcr2912 · Cited by 413
Targeted therapeutic options and future perspectives for HER2-positive breast cancer
Wang, J., & Xu, B. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0069-2 · Cited by 393
Metadherin, a cell surface protein in breast tumors that mediates lung metastasis
Brown, D. M., & Ruoslahti, E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00079-0 · Cited by 385
Bense, R. D., Sotiriou, C., Piccart-Gebhart, M. J., Haanen, J. B. A. G., van Vugt, M. A. T. M., de Vries, E. G. E., Schröder, C. P., & Fehrmann, R. S. N. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw192 · Cited by 379
Yeung, T.-L., Leung, C. S., Yip, K.-P., Au Yeung, C. L., Wong, S. T. C., & Mok, S. C. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00188.2015 · Cited by 377
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Holmgaard, R. B., Schaer, D. A., Li, Y., Castaneda, S. P., Murphy, M. Y., Xu, X., Inigo, I., Dobkin, J., Manro, J. R., Iversen, P. W., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0356-4 · Cited by 356 · cited 2×
“This study provided a better strategy for treating breast cancer that could enhance the anti-tumor effects in combination with programmed cell death 1 receptor ligand (PD-L1)/PD-1 checkpoint inhibitors and galunisertib [63].”
BackgroundEpidrugs: targeting epigenetic marks in cancer treatment
Miranda Furtado, C. L., Dos Santos Luciano, M. C., Silva Santos, R. D., Furtado, G. P., Moraes, M. O., & Pessoa, C. (2019) · Epigenetics · doi:10.1080/15592294.2019.1640546 · Cited by 345
Rizzo, P., Miao, H., D'Souza, G., Osipo, C., Yun, J., Zhao, H., Mascarenhas, J., Wyatt, D., Antico, G., Hao, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5744 · Cited by 341
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
Shafei, A., El-Bakly, W., Sobhy, A., Wagdy, O., Reda, A., Aboelenin, O., Marzouk, A., El Habak, K., Mostafa, R., Ali, M. A., et al. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.09.059 · Cited by 318
Caswell-Jin, J. L., Plevritis, S. K., Tian, L., Cadham, C. J., Xu, C., Stout, N. K., Sledge, G. W., Mandelblatt, J. S., & Kurian, A. W. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky062 · Cited by 315
Walter, M., Liang, S., Ghosh, S., Hornsby, P. J., & Li, R. (2009) · Oncogene · doi:10.1038/onc.2009.130 · Cited by 312
Marino, N., Woditschka, S., Reed, L. T., Nakayama, J., Mayer, M., Wetzel, M., & Steeg, P. S. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.06.012 · Cited by 309
Epigenetic alterations in cancer
Nirmaladevi, R. (2020) · Frontiers in Bioscience · doi:10.2741/4847 · Cited by 289
Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact
Foroni, C., Broggini, M., Generali, D., & Damia, G. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.001 · Cited by 282
Aharinejad, S., Paulus, P., Sioud, M., Hofmann, M., Zins, K., Schäfer, R., Stanley, E. R., & Abraham, D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0961 · Cited by 281
Targeting Notch signalling pathway of cancer stem cells
Venkatesh, V., Nataraj, R., Thangaraj, G. S., Karthikeyan, M., Gnanasekaran, A., Kaginelli, S. B., Kuppanna, G., Kallappa, C. G., & Basalingappa, K. M. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.02.02 · Cited by 275
Adipocyte biology in breast cancer: From silent bystander to active facilitator
Choi, J., Cha, Y. J., & Koo, J. S. (2018) · Progress in Lipid Research · doi:10.1016/j.plipres.2017.11.002 · Cited by 255
IL6/STAT3 Signaling Hijacks Estrogen Receptor α Enhancers to Drive Breast Cancer Metastasis
Siersbæk, R., Scabia, V., Nagarajan, S., Chernukhin, I., Papachristou, E. K., Broome, R., Johnston, S. J., Joosten, S. E. P., Green, A. R., Kumar, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.007 · Cited by 245
Targeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 233
Twist Modulates Breast Cancer Stem Cells by Transcriptional Regulation of CD24 Expression
Vesuna, F., Lisok, A., Kimble, B., & Raman, V. (2009) · Neoplasia · doi:10.1593/neo.91084 · Cited by 231
Plosker, G. L., & Faulds, D. (1993) · Drugs · doi:10.2165/00003495-199345050-00011 · Cited by 223
Mirza, S., Sharma, G., Parshad, R., Gupta, S. D., Pandya, P., & Ralhan, R. (2013) · Journal of Breast Cancer · doi:10.4048/jbc.2013.16.1.23 · Cited by 217
Harrington, L. S., Sainson, R. C. A., Williams, C. K., Taylor, J. M., Shi, W., Li, J.-L., & Harris, A. L. (2008) · Microvascular Research · doi:10.1016/j.mvr.2007.06.006 · Cited by 215
Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer
Dong, C., Wu, Y., Wang, Y., Wang, C., Kang, T., Rychahou, P. G., Chi, Y.-I., Evers, B. M., & Zhou, B. P. (2013) · Oncogene · doi:10.1038/onc.2012.169 · Cited by 214
Sarrió, D., Moreno‐Bueno, G., Hardisson, D., Sánchez‐Estévez, C., Guo, M., Herman, J. G., Gamallo, C., Esteller, M., & Palacios, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11197 · Cited by 209
DNMT1: A key drug target in triple-negative breast cancer
Wong, K. K. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.010 · Cited by 198
Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state
Shimoda, M., Principe, S., Jackson, H. W., Luga, V., Fang, H., Molyneux, S. D., Shao, Y. W., Aiken, A., Waterhouse, P. D., Karamboulas, C., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3021 · Cited by 197
Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis
Li, Z., Wang, D., Lu, J., Huang, B., Wang, Y., Dong, M., Fan, D., Li, H., Gao, Y., Hou, P., et al. (2020) · Cell Death & Differentiation · doi:10.1038/s41418-020-00615-9 · Cited by 196
Metabolic crosstalk in the breast cancer microenvironment
Dias, A. S., Almeida, C. R., Helguero, L. A., & Duarte, I. F. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.002 · Cited by 195
Yingling, J. M., McMillen, W. T., Yan, L., Huang, H., Sawyer, J. S., Graff, J., Clawson, D. K., Britt, K. S., Anderson, B. D., Beight, D. W., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.23795 · Cited by 187
Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
Polydorou, C., Mpekris, F., Papageorgis, P., Voutouri, C., & Stylianopoulos, T. (2017) · Oncotarget · doi:10.18632/oncotarget.15534 · Cited by 185
Qi, M., Xia, Y., Wu, Y., Zhang, Z., Wang, X., Lu, L., Dai, C., Song, Y., Xu, K., Ji, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28438-x · Cited by 182
Picon-Ruiz, M., Pan, C., Drews-Elger, K., Jang, K., Besser, A. H., Zhao, D., Morata-Tarifa, C., Kim, M., Ince, T. A., Azzam, D. J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0927 · Cited by 180
Breast-cancer stem cells—beyond semantics
Badve, S., & Nakshatri, H. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70191-7 · Cited by 174
Macrophage targeting: opening new possibilities for cancer immunotherapy
Cassetta, L., & Kitamura, T. (2018) · Immunology · doi:10.1111/imm.12976 · Cited by 166
The Many Faces of C/EBPδ and their Relevance for Inflammation and Cancer
Balamurugan, K., & Sterneck, E. (2013) · International Journal of Biological Sciences · doi:10.7150/ijbs.7224 · Cited by 165
Genome‐wide cooperation of EMT transcription factor ZEB 1 with YAP and AP ‐1 in breast cancer
Feldker, N., Ferrazzi, F., Schuhwerk, H., Widholz, S. A., Guenther, K., Frisch, I., Jakob, K., Kleemann, J., Riegel, D., Bönisch, U., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103209 · Cited by 165
Interplay of EMT and CSC in Cancer and the Potential Therapeutic Strategies
Tanabe, S., Quader, S., Cabral, H., & Ono, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00904 · Cited by 161
Si, W., Huang, W., Zheng, Y., Yang, Y., Liu, X., Shan, L., Zhou, X., Wang, Y., Su, D., Gao, J., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.04.011 · Cited by 160
Biomarkers for EMT and MET in breast cancer: An update
Liu, F., Gu, L., Shan, B.-E., Geng, C., & Sang, M. (2016) · Oncology Letters · doi:10.3892/ol.2016.5369 · Cited by 159
The key roles of cancer stem cell-derived extracellular vesicles
Su, C., Zhang, J., Yarden, Y., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00499-2 · Cited by 148
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Geenen, J. J. J., Linn, S. C., Beijnen, J. H., & Schellens, J. H. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0587-4 · Cited by 143
Role of novel histone modifications in cancer
Shanmugam, M. K., Arfuso, F., Arumugam, S., Chinnathambi, A., Jinsong, B., Warrier, S. R., Wang, L. Z., Kumar, A. P., Ahn, K. S., Sethi, G., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.23356 · Cited by 143
Notch in mammary gland development and breast cancer
Politi, K. A., Feirt, N. M., & Kitajewski, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.04.013 · Cited by 141
Signaling pathways governing breast cancer stem cells behavior
Song, K., & Farzaneh, M. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02321-w · Cited by 133
Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis
Eiró, N., González-Llorente, L., Martínez-Ordóñez, A., Fernández‐García, B., González, L. O., Cid, S., Domínguez, F., Pérez-Fernández, R., & Vizoso, F. J. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0371-y · Cited by 125
İmani, S., Hosseinifard, H., Cheng, J., Wei, C., & Fu, J. (2016) · Scientific Reports · doi:10.1038/srep28587 · Cited by 122
Ma, X., Yan, W., Dai, Z., Gao, X., Ma, Y., Xu, Q., Jiang, J., & Zhang, S. (2016) · Drug Design Development and Therapy · doi:10.2147/dddt.s102541 · Cited by 116
Wang, X., Wei, S., Zhao, Y., Shi, C., Liu, P., Zhang, C., Lei, Y., Zhang, B., Bai, B., Huang, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.034 · Cited by 114
Duan, H., Yan, Z., Chen, W., Wu, Y., Han, J., Guo, H., & Qiao, J. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.010 · Cited by 104
The to and fro of tumour spread
van Denderen, B. J. W., & Thompson, E. W. (2013) · Nature · doi:10.1038/493487a · Cited by 99
Jin, K., Pandey, N. B., & Popel, A. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0981-3 · Cited by 99
AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells
Hampsch, R. A., Wells, J. D., Traphagen, N. A., McCleery, C. F., Fields, J. L., Shee, K., Dillon, L. M., Pooler, D. B., Lewis, L. D., Demidenko, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0269 · Cited by 98
Locatelli, M., Aftimos, P. G., Dees, E. C., LoRusso, P. M., Pegram, M. D., Awada, A. H., Huang, B., Cesari, R., Jiang, Y., Shaik, M. N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13727 · Cited by 93
A Transcriptional Program Mediating Entry into Cellular Quiescence
Liu, H., Adler, A. S., Segal, E., & Chang, H. Y. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030091 · Cited by 92
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
Ye, L., Lin, C., Wang, X., Li, Q., Li, Y., Wang, M., Zhao, Z., Wu, X., Shi, D., Xiao, Y., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910638 · Cited by 84
Piha-Paul, S. A., Münster, P. N., Hollebecque, A., Argilés, G., Dajani, O. F., Cheng, J., Wang, R., Swift, A., Tosolini, A., & Gupta, S. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.06.115 · Cited by 77
C/EBPδ links IL-6 and HIF-1 signaling to promote breast cancer stem cell-associated phenotypes
Balamurugan, K., Mendoza-Villanueva, D., Sharan, S., Summers, G. H., Dobrolecki, L. E., Lewis, M. T., & Sterneck, E. (2018) · Oncogene · doi:10.1038/s41388-018-0516-5 · Cited by 74
The role of histone deacetylase inhibitors in metastatic breast cancer
Zucchetti, B. M., Shimada, A. K., Katz, A., & Curigliano, G. (2018) · The Breast · doi:10.1016/j.breast.2018.12.001 · Cited by 74
Zhuang, J., Huo, Q., Yang, F., & Xie, N. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.603552 · Cited by 74
Hu, W., Wang, Z., Zhang, S., Wu, J., Yu, K., Yu, K., Ji, A., Lu, W., Wang, Z., Wu, J., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-44048-y · Cited by 71
Yu, D. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90277-5 · Cited by 62
da Silveira, W. A., Palma, P. V. B., Sicchieri, R. D., Villacis, R. A. R., Mandarano, L. R. M., de Oliveira, T. M. G., Antônio, H. M. R., de Andrade, J. M., Muglia, V. F., Rogatto, S. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02761-6 · Cited by 47
Epigenetic arginine methylation in breast cancer: emerging therapeutic strategies
Wang, S.-C., Dowhan, D. H., & Muscat, G. E. O. (2019) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0224 · Cited by 44
Notch Signaling and the Breast Cancer Microenvironment
Shen, Q., & Reedijk, M. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55031-8_12 · Cited by 44
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
Ballester, B., Milara, J., & Cortijo, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27526 · Cited by 43
Sulforaphane inhibits mammary adipogenesis by targeting adipose mesenchymal stem cells
Li, Q., Xia, J., Yao, Y., Gong, D., Shi, H., & Zhou, Q. Y. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2672-1 · Cited by 43
A three layered histone epigenetics in breast cancer metastasis
Nandy, D., Rajam, S. M., & Dutta, D. (2020) · Cell & Bioscience · doi:10.1186/s13578-020-00415-1 · Cited by 43
Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy (Review)
Zhang, Y., Xie, Z., Guo, X., Xiao, X., & Xiong, L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10653 · Cited by 40
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities
Shah, K., & Rawal, R. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200103111539 · Cited by 39
DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood
Ennour‐Idrissi, K., Dragic, D., Issa, E., Michaud, A., Chang, S.-L., Provencher, L., Durocher, F., & Diorio, C. (2020) · Cancers · doi:10.3390/cancers12113088 · Cited by 35
Wu, Y. S., Lee, Z. Y., Chuah, L., Mai, C., & Ngai, S. C. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009618666180430130248 · Cited by 29
Mayer, E. L., Scheulen, M. E., Beckman, J. A., Richly, H., Duarte, A., Cotreau, M. M., Strahs, A. L., Agarwal, S., Steelman, L., Winer, E. P., et al. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2632-9 · Cited by 25
Slug/β-Catenin–Dependent Proinflammatory Phenotype in Hypoxic Breast Cancer Stem Cells
Storci, G., Bertoni, S., Carolis, S. D., Papi, A., Nati, M., Ceccarelli, C., Pirazzini, C., Garagnani, P., Ferrarini, A., Buson, G., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.020 · Cited by 22
Kast, R. E., Skuli, N., Cos, S., Karpel‐Massler, G., Shiozawa, Y., Goshen, R., & Halatsch, M. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s139963 · Cited by 21
Metadata
- Authors
- Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-18
- Volume
- 23
- Issue
- 12
- Pages
- 6806
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W4283122919
- Cited by
- 406
- References
- 117
- FWCI
- 29.55
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.